Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

atigue; AEs were consistent in severity and frequency to historical Peg-IFN/RBV treatment. There were no clinically significant, treatment-emergent trends in any clinical laboratory parameters.  

PSI-7977 with Peg-IFN/RBV resulted in rapid viral suppression, with all HCV GT2 or 3 patients (n=24) achieving both a rapid virologic response (RVR) and remaining below the limit of detection through the end of treatment at week 12 (EOT). No patient exhibited viral breakthrough. These HCV GT2 or 3 patients are now being monitored for an additional 24 weeks to assess SVR at 12 weeks (SVR12) and 24 weeks (SVR24) after the discontinuation of therapy. Initial data have been submitted for presentation at an upcoming major scientific conference scheduled to take place during the first half of 2011.

In addition to the ongoing Phase 2b dose-ranging study, we recently announced the initiation of an exploratory Phase 2 study of PSI-7977 and RBV with 0-12 weeks of interferon in patients with HCV GT2 or GT3.  During the second quarter of 2011, we also expect to initiate a 24-week Phase 2b study of PSI-7977 with Peg-IFN/RBV.

PSI-938In late November 2010, we initiated Part 2 of a Phase 1 study that includes the first combination of a purine (PSI-938) and a pyrimidine (PSI-7977) nucleotide analog for the treatment of HCV. The cohorts within Part 2 are evaluating PSI-938 300mg QD as monotherapy and in combination with PSI-7977 400mg QD. The primary objective is to assess the safety, tolerability and pharmacokinetics of PSI-938 alone and in combination with PSI-7977. The secondary objective of Part 2 is to evaluate the short-term change in HCV RNA.

Preliminary results with PSI-938 300mg QD administered as monotherapy for 14 days demonstrate:

  • PSI-938 was generally safe and well tolerated over 14 days
  • There were no serious adverse events, and no dose modifications or discontinuations
  • There were no clinically significan
    '/>"/>

  • SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
    3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
    4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
    5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
    6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
    7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
    8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
    9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
    10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
    11. Pharmasset Receives Notice of Allowance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... PARK, N.C. , Sept. 19, 2014 /PRNewswire/ ... on cloud-based drug design and development, partnering is ... company,s mission is to design new drugs and ... and 2 partners to further their development. The ... portfolio investments. To support this business model, Cloud ...
    (Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
    (Date:9/19/2014)... Sept. 19, 2014 The American Association for ... Design and Manufacturing has joined the AAHomecare Corporate Partner ... Harvey Diamond have been actively involved in AAHomecare ... it has quickly grown into a major global manufacturer ... Drive allows AAHomecare to increase efforts on behalf of ...
    Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
    ... Mich., March 6 NanoBio(R) Corporation has,received its third ... having successfully met three critical development milestones:,validating the efficacy ... and demonstrating the strength of its influenza vaccine in,ferret ... of Michigan, has received a,total of $30 million over ...
    ... lower cardiac toxicity drives ... investigator interest, ... MTA: CTIC) announced today that its investigational drug,pixantrone will be ... Charcot Stichting, in Brussels, Belgium, which sponsors a,consortium of centers ...
    Cached Medicine Technology:NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 3Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 4
    (Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... notes that yet another insurer has announced plans ... a statement posted on its website last month, ... such procedures effective November 1, 2014. The insurer ...
    (Date:9/20/2014)... 20, 2014 The excitement is building up once ... North Carolina. This year the Surry Arts Council will be ... around the country who are still fans of the Andy Griffith ... sitcom that aired on CBS from 1960 through 1968. The ... American television history. Mount Airy, North Carolina is where the ...
    (Date:9/20/2014)... September 20, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has launched a special ... company’s prom outfits are popular among worldwide clients. Now, ... wholesale prom dresses on its website. , ... customers from around the world. Great custom made items ...
    (Date:9/20/2014)... 2014 QueenBeeTickets.com is ready to offer ... performances. She will visit many cities in North America ... 16th of April. , Click Here to ... at QueenBeeTickets.com. , The star’s fans are not going ... favorite young singer in a live performance. Ariana Grande ...
    (Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
    Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
    ... , , , GAITHERSBURG, Md., ... Health and Human Services (HHS) has placed an order for an ... against the 2009 H1N1 influenza virus. This brings HHS orders ... total cumulative contract value of approximately $453 million. Previous HHS ...
    ... and minimally invasive techniques, study finds , MONDAY, Sept. ... is possible using either minimally invasive or traditional open ... for the type of fracture, researchers say. , The ... factors such as fracture type and degree of septal ...
    ... in times of uncertainty, people would gravitate toward familiar,favorites. But ... shows that stress and upheaval actually lead people to ... can name our favorite ,comfort foods, and believe that we ... stress and upheaval," writes author Stacy Wood (University of South ...
    ... , , Projects Target ... WASHINGTON, Sept. 21 Secretary of Veterans Affairs Eric K. Shinseki announced ... $1.4 billion as the Department,s share of spending under the American Recovery ... , , "In putting America back to work, we ...
    ... FRANCISCO, CA ─ SEPTEMBER 21, 2009 ... drug-eluting stents are effective with a low rate of ... 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored ... study, "The Effect of Drug-Eluting Stents on Clinical and ...
    ... 2009 A new type of sirolimus-eluting stent ... paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding ... SES over the PES stent for the trial,s primary ... RES-ELUTION I Trial on the safety and effectiveness of ...
    Cached Medicine News:Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 2Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 3Health News:Best Option for Fractured Nose Varies by Patient 2Health News:Comfort food fallacy: Upheaval leads to less-familiar choices 2Health News:Secretary Shinseki Announces Progress on $1.4 Billion in Recovery Act Spending 2Health News:Researchers find drug-eluting stents safe, effective for PCI in diabetics 2Health News:New type of sirolimus-eluting stent demonstrates superior results 2Health News:New type of sirolimus-eluting stent demonstrates superior results 3
    PremierEdge™ Stab Knives - 15°....
    VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
    Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
    Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
    Medicine Products: